Erenumab – 2018 Pipeline Review

Migraine is a debilitating disorder that affects millions of people in the United States. Migraine has the ability to affect individuals in a way that deprives them of their normal, daily activities, and often results in pain, physical impairment, lost productivity, and increased financial cost. Erenumab (Aimovig™, AMG-334) is a fully human monoclonal antibody being developed by Amgen Inc. in collaboration with Novartis Pharmaceuticals for the prevention of episodic and chronic migraine. Erenumab’s Biologics License Application was accepted on July 20, 2017, and the drug candidate has been granted an upcoming PDUFA date of May 17, 2018. Erenumab has the potential to benefit patients who have experienced multiple treatment failures and have limited options available to them.

For our complete review of Erenumab:

Executive Summary of Evaluation:


Erenumab (Amgen Inc. / Novartis Pharmaceuticals)







  FDA Standard Review Designation


  Patent Expiration


Indications Migraine

Submitted for Approval (BLA)

Efficacy Migraine

Efficacy reported in Phase III Trials


“Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments.” Amgen, 22 Jan. 2018,

Clinical Trial data obtained at Accessed: March 9, 2018.

Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 Jan 1:333102418759786.

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017 Nov 30;377(22):2123-2132.

Pharma Intelligence Center Accessed: March 2, 2018.

Pipeline Update:

Aimovig (erenumab-aooe) obtained approval status from the FDA on May 17, 2018 meeting the PDUFA date.  The following link with take you to the FDA press announcement.  The package insert can also be accessed here.

 Additional 2018 Pipeline Reviews are available for the following drugs.



Rituximab Biosimilars


Coauthored by: Kristen Ciampi, PharmD Candidate

Kristen is a sixth-year pharmacy student at the University of Rhode Island. Kristen is completing her studies through an advanced pharmacy practice rotation at RJ Health Systems prior to graduating with a PharmD degree in May of 2018.

For our complete review of Erenumab: